Arthritis News and Research

Latest Arthritis News and Research

Platelet Rich Plasma Therapy reduces pain and improves function in knee osteoarthritis patients

The first American study that positions Platelet Rich Plasma Therapy (PRP) as a viable means in managing knee osteoarthritis, appeared today in the December issue of the American Journal of Physical Medicine & Rehabilitation (AJPMR). The study, authored by Dr. Steven Sampson of the Orthohealing Center in Los Angeles, details the account of 14 patients with primary and secondary knee osteoarthritis receiving three platelet-rich plasma injections in the affected knee at 4-week intervals with one year follow up.

20 Nov 2010

Experts formulate research related to psychological adjustment and traumatic brain injury

Five U.S. federal agencies recently cosponsored a set of expert work groups to formulate common data elements for research related to psychological adjustment and traumatic brain injury (TBI).

19 Nov 2010

Scientists discover bone matrix plays a vital role in tissue hardening

Scientists are reporting the first direct evidence that a subtle change in the physical properties of a tissue can affect its function. The finding has immediate implications for understanding several rare hearing disorders, they said, and ultimately could offer insight into such conditions as osteoporosis, arthritis, cardiovascular disease and cancer.

19 Nov 2010

OSEO awards €10.4 million to DIPPAL project targeting Alzheimer's disease

The biotech companies PHARNEXT and BIOSYSTEMS INTERNATIONAL, the Bordeaux Hospital where CMRR is located, the university Bordeaux Segalen and Inserm (the center U897 "Epidemiology and Biostatistics") have joined forces to carry out the DIPPAL2i project. This innovative research and industrial development project is targeting Alzheimer's disease (AD) and has attracted significant financial support from OSEO (the French state innovation agency).

18 Nov 2010

Multiple pain locations contribute to greater knee pain

A new study found that patients with osteoarthritis (OA) of the knee who also have pain in other joints were more likely to experience greater knee pain. Specifically, pain in the lower back as well as foot pain and elbow pain on the same side as the affected knee were associated with more severe knee pain. Full details appear in the December issue of Arthritis Care & Research, a journal published by Wiley-Blackwell on behalf of the American College of Rheumatology.

18 Nov 2010

LFA encouraged by FDA Advisory Committee vote on BENLYSTA for autoimmune disease lupus

Today the U.S. Food and Drug Administration (FDA) Arthritis Advisory Committee voted overwhelmingly (13 to 2) to recommend BENLYSTA® for approval as a treatment for the autoimmune disease lupus. If FDA approved, BENLYSTA would become the first new treatment for lupus in 52 years. While today's vote is a positive step, the FDA still must make a final decision to approve BENLYSTA in the coming weeks.

17 Nov 2010

LRI pleased with FDA Advisory Committee's approval of Benlysta for lupus

The Lupus Research Institute (LRI) and its National Coalition of state and local lupus organizations are pleased with the U.S. Food and Drug Administration (FDA) Advisory Committee's vote to recommend approval of Benlysta® for active systemic lupus erythematosus (SLE), offering patients new found hope for the first approved treatment option in more than 50 years.

17 Nov 2010

FDA Arthritis Advisory Committee recommends approval of BENLYSTA for SLE

Human Genome Sciences, Inc. and GlaxoSmithKline PLC today announced that the Arthritis Advisory Committee of the U.S. Food and Drug Administration (FDA) has voted 13 to 2 to recommend that the FDA approve BENLYSTA (belimumab) for the treatment of autoantibody-positive patients with active systemic lupus erythematosus (SLE).

17 Nov 2010

BUSM professor wins 2010 Maurice Wood Award for Lifetime Contribution to Primary Care Research

Larry Culpepper, MD, MPH, chair and professor of family medicine at Boston University School of Medicine (BUSM) and chief of family medicine at Boston Medical Center (BMC), is the recipient of the 2010 Maurice Wood Award for Lifetime Contribution to Primary Care Research.

16 Nov 2010

4SC to present development of resminostat and preclinical drug candidates at EORTC-NCI-AACR symposium

4SC, a drug discovery and development company focused on autoimmune and cancer indications, today announced that it will present four posters and respective abstracts that highlight the development of its lead oncology compound resminostat and several preclinical drug candidates at the 22nd EORTC-NCI-AACR symposium from 16 - 19 November, 2010 in Berlin, Germany.

16 Nov 2010

IFPA announces winner of Under the Spotlight Award for psoriasis documentary

125 million people worldwide suffer from psoriasis and the hardships this difficult disease brings. Today, on the International Day of Tolerance we are very proud to announce the winner of the 1st Under the Spotlight Award for Best International Documentary on Psoriasis.

16 Nov 2010

Scientists reveal that homeopathic consultations can reduce symptoms of rheumatoid arthritis

New evidence that homeopathic consultations can reduce the symptoms of rheumatoid arthritis has been revealed by scientists from the University of Southampton.

16 Nov 2010

Adeona third quarter total net revenues increase to $289,898

Adeona Pharmaceuticals, Inc., a developer of innovative medicines for serious central nervous system diseases, announced its third quarter 2010 financial results as well as recent clinical and operational achievements.

15 Nov 2010

Santarus announces commercial U.S. launch of CYCLOSET for type 2 diabetes mellitus

Santarus, Inc., a specialty biopharmaceutical company, today announced the commercial U.S. launch of CYCLOSET (bromocriptine mesylate) tablets. CYCLOSET is a prescription drug approved by the U.S. Food and Drug Administration (FDA) as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus both as monotherapy and in combination with other oral antidiabetic agents.

15 Nov 2010

Young father receives life-saving intervention prior heart transplant surgery

James "Jimmy" Armstrong hadn't missed a "Mac" in 28 years. At 44, he's one of the youngest "goats" in the Chicago Yacht Club. Sailors receive the designation of "goat" once they've completed 20 or more "Macs", the 333-mile boat race from Chicago to Mackinac, Mich. Armstrong has sailed the race every year since he was 16. But, he wasn't among the sailors this past July. Instead, he was in intensive care awaiting heart transplant following a harrowing experience spurred by severe case of myocarditis-a little-known condition causing inflammation of the heart muscle.

15 Nov 2010

VIMOVO granted marketing and pricing approval in the UK

POZEN Inc., a pharmaceutical company committed to transforming medicine that transforms lives, today announced that it has been notified by AstraZeneca that marketing and pricing approval for VIMOVO™ (naproxen/ esomeprazole magnesium) 500/20 mg modified-release tablets, has been granted in the United Kingdom (UK).

12 Nov 2010

Elevated levels of MCP-1 found in urine of patients with acute kidney injury

The presence of certain markers in the urine might be a red flag for acute kidney injury (AKI), according to a study appearing in an upcoming issue of the Journal of the American Society Nephrology (JASN). The results suggest that a simple urine test could help prevent cases of kidney failure.

12 Nov 2010

Poll finds Americans' conflicting views about public health system

A comprehensive review of national opinion polls shows that Americans have conflicting views about the nation's public health system and are divided along partisan lines in their support of additional spending on public health programs. A majority supports increased spending on public health in general and sees public health interventions as saving money in the long term.

11 Nov 2010

Incyte presents data on INCB28050 Phase IIa trial for rheumatoid arthritis at ACR/ARHP Meeting

Incyte Corporation announced the presentation of final six-month clinical data from the dose ranging, placebo-controlled Phase IIa trial of its orally available janus kinase (JAK) inhibitor INCB28050 in patients with active rheumatoid arthritis (RA).

11 Nov 2010

4SC 2010 first nine months revenue decreases from EUR1.4 million to EUR0.8 million

4SC, a drug discovery and development company focused on autoimmune and cancer indications, today announced its financial results in accordance with International Financial Reporting Standards (IFRS) for the first nine months of 2010, which ended on 30 September 2010.

11 Nov 2010

Arthritis News and Research

Latest Arthritis News and Research

Platelet Rich Plasma Therapy reduces pain and improves function in knee osteoarthritis patients

Experts formulate research related to psychological adjustment and traumatic brain injury

Scientists discover bone matrix plays a vital role in tissue hardening

OSEO awards €10.4 million to DIPPAL project targeting Alzheimer's disease

Multiple pain locations contribute to greater knee pain

LFA encouraged by FDA Advisory Committee vote on BENLYSTA for autoimmune disease lupus

LRI pleased with FDA Advisory Committee's approval of Benlysta for lupus

FDA Arthritis Advisory Committee recommends approval of BENLYSTA for SLE

BUSM professor wins 2010 Maurice Wood Award for Lifetime Contribution to Primary Care Research

4SC to present development of resminostat and preclinical drug candidates at EORTC-NCI-AACR symposium

IFPA announces winner of Under the Spotlight Award for psoriasis documentary

Scientists reveal that homeopathic consultations can reduce symptoms of rheumatoid arthritis

Adeona third quarter total net revenues increase to $289,898

Santarus announces commercial U.S. launch of CYCLOSET for type 2 diabetes mellitus

Young father receives life-saving intervention prior heart transplant surgery

VIMOVO granted marketing and pricing approval in the UK

Elevated levels of MCP-1 found in urine of patients with acute kidney injury

Poll finds Americans' conflicting views about public health system

Incyte presents data on INCB28050 Phase IIa trial for rheumatoid arthritis at ACR/ARHP Meeting

4SC 2010 first nine months revenue decreases from EUR1.4 million to EUR0.8 million

Leveraging the Radian ASAP in standard casework

A journey through science, software, and innovation: Insights from the Bruker software team

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Arthritis News and Research

Latest Arthritis News and Research

Leveraging the Radian ASAP in standard casework

A journey through science, software, and innovation: Insights from the Bruker software team

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Newsletters you may be interested in